Table of Contents
- What is STRO-002?
- How Does STRO-002 Work?
- What Cancers Does STRO-002 Treat?
- Clinical Trials for STRO-002
- Administration and Dosing
- Potential Side Effects
- Combination Therapy with Bevacizumab
- Future Prospects
What is STRO-002?
STRO-002 is a new type of cancer treatment called an antibody-drug conjugate (ADC). This means it combines two parts: an antibody (a protein that targets specific cells) and a drug that can kill cancer cells. STRO-002 is designed to specifically target cancer cells while minimizing damage to healthy cells[1].
How Does STRO-002 Work?
STRO-002 works by targeting a protein called folate receptor alpha (FolRα), which is found in high amounts on some cancer cells. The antibody part of STRO-002 attaches to this protein, allowing the drug to be delivered directly to the cancer cells. This targeted approach may help reduce side effects compared to traditional chemotherapy, which affects both healthy and cancerous cells[1].
What Cancers Does STRO-002 Treat?
STRO-002 is being studied for the treatment of several types of cancers, including:
- Ovarian cancer (also called ovarian carcinoma or ovary cancer)
- Fallopian tube cancer
- Primary peritoneal carcinoma (cancer that starts in the lining of the abdomen)
- Endometrial cancer (cancer of the uterus lining)
These cancers are often grouped together because they behave similarly and are treated in much the same way[1][2].
Clinical Trials for STRO-002
STRO-002 is currently being studied in clinical trials. These are research studies that help doctors understand how well a new treatment works and if it’s safe. There are two main trials for STRO-002:
A Phase 1 trial studying STRO-002 alone in patients with advanced ovarian and endometrial cancers. This trial is looking at different doses of STRO-002 to find the best dose for future studies[1].
Another Phase 1 trial studying STRO-002 in combination with a drug called bevacizumab (also known as Avastin) in patients with advanced ovarian cancer. This trial is trying to see if combining these two drugs might work better than either drug alone[2].
Administration and Dosing
STRO-002 is given as an intravenous (IV) infusion, which means it’s delivered directly into the bloodstream through a vein. In the clinical trials, it’s being given once every 3 weeks. The exact dose is still being determined through the trials[1].
Potential Side Effects
As with any new treatment, understanding the side effects of STRO-002 is an important part of the clinical trials. The researchers are carefully monitoring patients for any adverse events (side effects). They’re also looking at how the drug affects things like blood tests and other laboratory values. This information helps determine if STRO-002 is safe and tolerable for patients[1][2].
Combination Therapy with Bevacizumab
One of the clinical trials is studying STRO-002 in combination with another drug called bevacizumab (Avastin). Bevacizumab is an anti-VEGF agent, which means it works by blocking the growth of new blood vessels that tumors need to grow. By combining these two drugs, researchers hope to see if they can improve the effectiveness of treatment for patients with advanced ovarian cancer[2].
Future Prospects
The ongoing clinical trials for STRO-002 are designed to answer important questions about this new treatment, including:
- How safe is STRO-002 for patients?
- What’s the best dose to use?
- How effective is it at treating cancer?
- How does the body process the drug (pharmacokinetics)?
- Does it work better alone or in combination with other drugs?
The results of these trials will help determine if STRO-002 could become a new treatment option for patients with ovarian, endometrial, and related cancers in the future[1][2].
